Juan Vera Insider Information
For the past 12 years, Juan F. Vera has worked extensively on developing novel T cell therapies and optimizing manufacturing processes for clinical applications at the Center for Cell and Gene Therapy (CAGT) at Baylor College of Medicine. In collaboration with Wilson Wolf Manufacturing, he has been instrumental in the design and testing of the G-Rex® cell culture platform and pioneered its use for the large-scale production of T cells. Dr. Vera has extensive expertise in developing and streamlining therapeutic candidates from the research bench to the cGMP facility while ensuring robust production and scalability. Dr. Vera has previously collaborated with Celgene and Bluebird Bio in developing novel CAR T cell therapies. He has also been the recipient of different prestigious awards including the Idea Development Award from the Department of Defense and Mentored Research Scholar Award from the American Cancer Society. Dr. Vera attained his M.D. from the University El Bosque in Bogota, Colombia.
What is Juan Vera's net worth?
The estimated net worth of Juan Vera is at least $1.02 million as of March 16th, 2021. Dr. Vera owns 2,564,487 shares of Marker Therapeutics stock worth more than $1,024,256 as of August 15th. This net worth evaluation does not reflect any other assets that Dr. Vera may own. Learn More about Juan Vera's net worth.
How old is Juan Vera?
Dr. Vera is currently 42 years old. There are 4 older executives and no younger executives at Marker Therapeutics. The oldest executive at Marker Therapeutics is Mr. Michael J. Loiacono, Chief Accounting Officer, Treasurer & Sec., who is 56 years old. Learn More on Juan Vera's age.
How do I contact Juan Vera?
Has Juan Vera been buying or selling shares of Marker Therapeutics?
Juan Vera has not been actively trading shares of Marker Therapeutics during the past quarter. Most recently, on Tuesday, March 16th, Juan Vera bought 571,428 shares of Marker Therapeutics stock. The stock was acquired at an average cost of $1.75 per share, with a total value of $999,999.00. Following the completion of the transaction, the insider now directly owns 2,564,487 shares of the company's stock, valued at $4,487,852.25. Learn More on Juan Vera's trading history.
Juan Vera Insider Trading History at Marker Therapeutics
| Transaction Date | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/16/2021 | Buy | 571,428 | $1.75 | $999,999.00 | 2,564,487 |  |
Marker Therapeutics Company Overview
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
Read More
Volume
384,887 shs
Average Volume
1,080,709 shs
Market Capitalization
$33.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.28
